◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

iShares Biotechnology ETF (IBB) ETF Overview

Name: iShares Biotechnology ETF (IBB) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Health · DATA UPDATED 2026-08-16

iShares Biotechnology ETF (IBB) is an exchange-traded fund managed by iShares in the "Health" category. It manages roughly $9 billion in assets.

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Interactive chart & fund stats →

IBB Fund Statistics

Expense ratio	0.44%
Trailing yield	0.22%
Assets under management	$9 billion
Fund category	Health
Fund family	iShares
Inception	2001-02-05

The live price chart, fund profile and news are in the interactive IBB viewer.

Other Companies in Health

XLV · State Street Health Care Select Sector SPDR ETF — $42 billion
VHT · Vanguard Health Care Index Fund ETF Shares — $21 billion
XBI · State Street SPDR S&P Biotech ETF — $10 billion
IXJ · iShares Global Healthcare ETF — $4 billion
IYH · iShares U.S. Healthcare ETF — $4 billion

← IBAI All “I” companies IBCP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.